JP2023507740A5 - - Google Patents
Info
- Publication number
- JP2023507740A5 JP2023507740A5 JP2022537008A JP2022537008A JP2023507740A5 JP 2023507740 A5 JP2023507740 A5 JP 2023507740A5 JP 2022537008 A JP2022537008 A JP 2022537008A JP 2022537008 A JP2022537008 A JP 2022537008A JP 2023507740 A5 JP2023507740 A5 JP 2023507740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- lcdr1
- lcdr2
- hcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024200599A JP2025015730A (ja) | 2019-12-20 | 2024-11-18 | Ｐｓｍａに結合する抗原結合ドメイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1919019.8 | 2019-12-20 | ||
| GBGB1919019.8A GB201919019D0 (en) | 2019-12-20 | 2019-12-20 | Antigen-binding domain |
| PCT/GB2020/053289 WO2021123810A1 (en) | 2019-12-20 | 2020-12-18 | Antigen-binding domain binding to psma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024200599A Division JP2025015730A (ja) | 2019-12-20 | 2024-11-18 | Ｐｓｍａに結合する抗原結合ドメイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023507740A JP2023507740A (ja) | 2023-02-27 |
| JP2023507740A5 true JP2023507740A5 (enExample) | 2023-10-26 |
| JP7600240B2 JP7600240B2 (ja) | 2024-12-16 |
Family
ID=69322734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537008A Active JP7600240B2 (ja) | 2019-12-20 | 2020-12-18 | Ｐｓｍａに結合する抗原結合ドメイン |
| JP2024200599A Pending JP2025015730A (ja) | 2019-12-20 | 2024-11-18 | Ｐｓｍａに結合する抗原結合ドメイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024200599A Pending JP2025015730A (ja) | 2019-12-20 | 2024-11-18 | Ｐｓｍａに結合する抗原結合ドメイン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12496314B2 (enExample) |
| EP (1) | EP4076509A1 (enExample) |
| JP (2) | JP7600240B2 (enExample) |
| CN (1) | CN114828879A (enExample) |
| AU (1) | AU2020406862A1 (enExample) |
| CA (1) | CA3161844A1 (enExample) |
| GB (1) | GB201919019D0 (enExample) |
| WO (1) | WO2021123810A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| IL322575A (en) * | 2023-02-10 | 2025-10-01 | Amunix Pharmaceuticals Inc | Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use |
| JP2026507228A (ja) | 2023-03-03 | 2026-02-27 | アーセナル バイオサイエンシズ インコーポレイテッド | Ｐｓｍａ及びｃａ９を標的とするシステム |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| ES2674567T3 (es) * | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| EP3243837A4 (en) | 2015-01-08 | 2018-12-05 | Kyowa Hakko Kirin Co., Ltd. | Bispecific antibody binding to trailr2 and psma |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| WO2017180713A1 (en) * | 2016-04-13 | 2017-10-19 | Orimabs Ltd. | Anti-psma antibodies and use thereof |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| WO2019173324A1 (en) | 2018-03-06 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| WO2019173636A1 (en) * | 2018-03-07 | 2019-09-12 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
| CN108640999B (zh) | 2018-03-27 | 2021-08-13 | 广东万海细胞生物科技有限公司 | 一种靶向表达psma表面抗原的细胞的嵌合抗原受体 |
| CN110526976A (zh) | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526984A (zh) | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
-
2019
- 2019-12-20 GB GBGB1919019.8A patent/GB201919019D0/en not_active Ceased
-
2020
- 2020-12-18 EP EP20838216.8A patent/EP4076509A1/en not_active Withdrawn
- 2020-12-18 WO PCT/GB2020/053289 patent/WO2021123810A1/en not_active Ceased
- 2020-12-18 JP JP2022537008A patent/JP7600240B2/ja active Active
- 2020-12-18 CA CA3161844A patent/CA3161844A1/en active Pending
- 2020-12-18 US US17/784,392 patent/US12496314B2/en active Active
- 2020-12-18 CN CN202080088886.3A patent/CN114828879A/zh active Pending
- 2020-12-18 AU AU2020406862A patent/AU2020406862A1/en active Pending
-
2024
- 2024-11-18 JP JP2024200599A patent/JP2025015730A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512132A (ja) | 抗クローディン抗体及びそれらの使用 | |
| JP2024109678A5 (enExample) | ||
| JP7785284B2 (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2022058345A5 (enExample) | ||
| JP2021514664A5 (enExample) | ||
| SA521422116B1 (ar) | أجسام مضادة لـ pd-1 جديدة | |
| CN114502591A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2020522281A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| CN107151269A (zh) | 一种pdl‑1抗体、其药物组合物及其用途 | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2023540526A5 (enExample) | ||
| EP3166973A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| US20250179195A1 (en) | Anti-flt3 antibodies and compositions | |
| JP2020533965A5 (enExample) | ||
| JP2021517459A5 (enExample) | ||
| JP2021512652A5 (enExample) | ||
| CA3150030A1 (en) | Methods for identification of antigen binding specificity of antibodies | |
| JP2023509373A5 (enExample) | ||
| JP2020531003A5 (enExample) | ||
| JP2024522075A5 (enExample) | ||
| JP2019509714A5 (enExample) |